Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB1 | P08588 | 6/20 | 0.40 |
| ▸ | ADRB2 | P07550 | 10/20 | 0.39 |
| ▸ | BRD4 | O60885 | 1/20 | 0.38 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | DRD2 | P14416 | 3/20 | 0.38 |
| ▸ | DRD1 | P21728 | 3/20 | 0.38 |
| ▸ | DRD4 | P21917 | 3/20 | 0.38 |
| ▸ | DRD3 | P35462 | 3/20 | 0.38 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.37 |
| ▸ | FAAH | O00519 | 1/20 | 0.36 |
| ▸ | CNR1 | P21554 | 1/20 | 0.36 |
| ▸ | CNR2 | P34972 | 1/20 | 0.36 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL632130 | 0.88 | ADRB2 (0.37) | ADRB1ADRB2BRD4CREBBPMAPT | |
| SCHEMBL10982611 | 0.87 | BRD4 (0.37) | ADRB1ADRB2BRD4CREBBPMAPT | |
| SCHEMBL1558720 | 0.87 | MAPT (0.50) | ADRB1ADRB2BRD4CREBBPMAPT | |
| SCHEMBL11032765 | 0.85 | FOLH1 (0.39) | ADRB1ADRB2BRD4CREBBPMAPT | |
| SCHEMBL9909633 | 0.85 | SMN1; SMN2 (0.44) | ADRB1ADRB2BRD4CREBBPMAPT | |
| SCHEMBL1559916 | 0.85 | ADRB2 (0.39) | ADRB1ADRB2BRD4CREBBPMAPT | |
| Water SCHEMBL6406913 | 0.85 | ADRB2 (0.39) | ADRB1ADRB2BRD4CREBBPMAPT | |
| Hydrochloric Acid SCHEMBL11081263 | 0.83 | ADRB1 (0.37) | ADRB1ADRB2BRD4CREBBPMAPT | |
| SCHEMBL11088924 | 0.82 | BRD4 (0.34) | ADRB1ADRB2BRD4CREBBPMAPT | |
| SCHEMBL13437541 | 0.80 | BRD4 (0.35) | ADRB1ADRB2BRD4CREBBPMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1901776-B1 | NOVEL MEDICINAL COMBINATIONS WHICH ARE USED FOR TREATING RESPIRATORY TRACT DISEASES AND CONTAIN BETA-2 LONG-ACTING AGONISTS AND AT LEAST ONE OTHER TYPE OF ACTIVE SUBSTANCE | BOEHRINGER INGELHEIM INT (DE) | 2012-02-22 | — | — | EP | disclosed |
| EP-1761509-B1 | SUBSTITUTED CYCLOALKYL DERIVATIVES FOR THE TREATMENT OF RESPIRATORY DISEASES | BOEHRINGER INGELHEIM INT (DE) | 2011-05-04 | — | — | EP | disclosed |
| EP-1911749-B1 | New long-working Beta-2 agonists and their use as medicine | BOEHRINGER INGELHEIM INT (DE) | 2010-10-27 | — | — | EP | disclosed |
| US-7632834-B2 | Long acting beta-2-agonists and their use as medicaments | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-12-15 | — | — | US | disclosed |
| US-7563806-B2 | Substituted cycloalkyl derivatives, process for the manufacture thereof and use thereof as medicament | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-07-21 | — | — | US | disclosed |
| US-7423035-B2 | Substituted cycloalkyl derivatives, process for the manufacture thereof and use thereof as medicament | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-09-09 | — | — | US | disclosed |
| US-20080194550-A1 | LONG ACTING BETA-2-AGONISTS AND THEIR USE AS MEDICAMENTS | BOUYSSOU THIERRY | 2008-08-14 | — | — | US | disclosed |
| US-7402598-B2 | Arylethanolamine β2-adrenoreceptor agonist compounds | GLAXO GROUP LIMITED (GB) | 2008-07-22 | — | — | US | disclosed |
| US-20080146554-A1 | Substituted Cycloalkyl Derivatives, Process for the Manufacture thereof and Use thereof as Medicament | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-06-19 | — | — | US | disclosed |
| US-7375104-B2 | Long acting beta-2-agonists and their use as medicaments | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-05-20 | — | — | US | disclosed |
| US-7160882-B2 | Long acting β-2-agonists and their use as medicaments | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-01-09 | — | — | US | disclosed |
| EP-1711480-A1 | NOVEL LONG-WORKING BETA-2-AGONISTS AND USE THEREOF AS MEDICAMENTS | Boehringer Ingelheim International GmbH (DE) | 2006-10-18 | — | — | EP | disclosed |
| US-20060111344-A1 | Arylethanolamine beta2-adrenoreceptor agonist compounds | GLAXO GROUP LIMITED (GB) | 2006-05-25 | — | — | US | disclosed |
| WO-2005111002-A2 | SUBSTITUTED CYCLOALKYL DERIVATIVES FOR USE IN THE TREATMENT OF RESPIRATORY DISEASES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2005-11-24 | — | — | WO | disclosed |
| US-20050261286-A1 | Substituted cycloalkyl derivatives, process for the manufacture thereof and use thereof as medicament | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2005-11-24 | — | — | US | disclosed |
| EP-1595873-A1 | Substituted cycloalkyl derivatives for the treatment of respiratory diseases | Boehringer Ingelheim Pharma GmbH & Co.KG (DE) | 2005-11-16 | — | — | EP | disclosed |
| US-20050227975-A1 | New long acting beta-2-agonists and their use as medicaments | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2005-10-13 | — | — | US | disclosed |
| WO-2005070908-A1 | NOVEL LONG-WORKING BETA-2-AGONISTS AND USE THEREOF AS MEDICAMENTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2005-08-04 | — | — | WO | disclosed |
| EP-1525180-A2 | ARYLETHANOLAMINE BETA2-ADRENORECEPTOR AGONIST COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2005-04-27 | — | — | EP | disclosed |
| WO-2004016578-A2 | ARYLETHANOLAMINE BETA2-ADRENORECEPTOR AGONIST COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2004-02-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060111344-A1 | Arylethanolamine beta2-adrenoreceptor agonist compounds | ADRB2, ADRB1, ADRA2A | ADRB1 2/4885ADRB2 1/4885BRD4 862/4885 |
| US-20050227975-A1 | New long acting beta-2-agonists and their use as medicaments | ADRB2, ADRA2A, ADRB1 | ADRB1 3/4885ADRB2 1/4885BRD4 1913/4885 |
| US-20080146554-A1 | Substituted Cycloalkyl Derivatives, Process for the Manufacture thereof and Use thereof as Medicament | CHRM1, CHRM2, CHRM3 | ADRB1 40/4885ADRB2 83/4885BRD4 1952/4885 |
| US-20050261286-A1 | Substituted cycloalkyl derivatives, process for the manufacture thereof and use thereof as medicament | CHRM1, CHRM2, CHRM3 | ADRB1 40/4885ADRB2 83/4885BRD4 1952/4885 |
| US-20080194550-A1 | LONG ACTING BETA-2-AGONISTS AND THEIR USE AS MEDICAMENTS | ADRB2, ADRB1, CHRM1 | ADRB1 2/4885ADRB2 1/4885BRD4 1287/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.